| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 55.1 | 54.5 |
| Profit before tax | 6.2 | 9.2 |
| Net income | 6.0 | 8.8 |
| EPS (diluted, $ a share) | $0.11 | $0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -32.7% |
|---|---|
| Revenue, year on year | +1.1% |
| Operating margin | 9.6% |
10-Q filed with the SEC, NASDAQ: PBYI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Puma Biotechnology, Inc.: key numbers
- Share price
- $7.34Close, Nov 16
- Market cap
- $379M
- Shares outstanding
- 51.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Puma Biotechnology, Inc.
All →Puma Biotechnology Insider Michael Patrick Miller Sells $121K of Stock
Michael Patrick Miller sold 15,000 shares of Puma Biotechnology, Inc. at $8.10 a share, worth $121K in total on Nov 11, 2026. Shares held after the trade: 66,000 (-18.5%).
- Value
- $121K
- Shares
- 15,000
- Price
- $8.10
- Holding change
- -18.5%
- Trade date
- Nov 11, 2026
Puma Biotechnology Financial Results
Puma Biotechnology reported Q3 2026 financial results with total product revenue of $54.1 million, driven by sales of NERLYNX. The company reported GAAP net income of $6.0 million and raised its full-year 2026 net income guidance while continuing to advance its alisertib clinical development programs.
- Term
- Q3 2026
“Third quarter U.S. NERLYNX sales were positively impacted by increased year-over-year demand and were negatively impacted by higher than expected gross to net due to an increase in Medicaid and 340B sales, as well as a delay in sales to Puma’s ex-U.S. commercial partners that shifted from the third quarter to the fourth quarter.”
Alan H. Auerbach, Chairman, Chief Executive Officer and President
“We continue to anticipate increased year-over-year demand for NERLYNX, while we continue to advance alisertib across our ALISCA® clinical development programs.”
Alan H. Auerbach, Chairman, Chief Executive Officer and President
Puma Biotechnology Insider Troy Edward Wilson Sells $45.5K of Stock
Troy Edward Wilson sold 5,000 shares of Puma Biotechnology, Inc. at $9.10 a share, worth $45.5K in total on Sep 14, 2026. Shares held after the trade: 54,750 (-8.4%).
- Value
- $45.5K
- Shares
- 5,000
- Price
- $9.10
- Holding change
- -8.4%
- Trade date
- Sep 14, 2026
Puma Biotechnology Insider Alessandra Cesano Sells $567K of Stock
Alessandra Cesano sold 62,150 shares of Puma Biotechnology, Inc. at $9.12 a share, worth $567K in total on Sep 14, 2026. Shares held after the trade: 56,700 (-52.3%).
- Value
- $567K
- Shares
- 62,150
- Price
- $9.12
- Holding change
- -52.3%
- Trade date
- Sep 14, 2026